A study of HER2 gene amplification and protein expression in gastric cancer. Yan, B., Yau, E. X., Bte Omar, S. S., Ong, C. W., Pang, B., Yeoh, K. G., & Salto-Tellez, M. Journal of Clinical Pathology, August, 2010.
A study of HER2 gene amplification and protein expression in gastric cancer [link]Paper  doi  abstract   bibtex   
Background Gastric cancer is a leading cause of cancer-related mortality, and current treatment outcomes for advanced disease remain poor. HER2 has been identified as a potential candidate for targeted therapy in gastric cancers displaying HER2 gene amplification and protein overexpression. Aims To study the prevalence rate of HER2 gene amplification/overexpression in a local population, and determine the concordance rate between the various modalities. Methods 128 gastric cancer samples were analysed by fluorescence (FISH) and chromogenic (CISH) in situ hybridisation and immunohistochemistry (IHC). The relation between HER2 status and various clinicopathological parameters was also analysed. Results 11.7% (15/128) and 9.4% (12/128) of gastric cancers displayed HER2 gene amplification and protein overexpression (score 3+), respectively, with a perfect correlation between the FISH and CISH analyses. There was also a significant inverse correlation between overall survival and HER2 protein overexpression in intestinal-type gastric carcinomas (p\textless0.05). Conclusion Results, besides corroborating existing reports that discrepancies exist between HER2 ISH and IHC assays, also suggest the need to rigorously evaluate CISH as an independent reference standard for assessment of HER2 amplification in gastric cancers.
@article{yan_study_2010,
	title = {A study of {HER2} gene amplification and protein expression in gastric cancer},
	issn = {1472-4146},
	url = {http://www.ncbi.nlm.nih.gov/pubmed/20696687},
	doi = {10.1136/jcp.2010.076570},
	abstract = {Background Gastric cancer is a leading cause of cancer-related mortality, and current treatment outcomes for advanced disease remain poor. HER2 has been identified as a potential candidate for targeted therapy in gastric cancers displaying HER2 gene amplification and protein overexpression. Aims To study the prevalence rate of HER2 gene amplification/overexpression in a local population, and determine the concordance rate between the various modalities. Methods 128 gastric cancer samples were analysed by fluorescence (FISH) and chromogenic (CISH) in situ hybridisation and immunohistochemistry (IHC). The relation between HER2 status and various clinicopathological parameters was also analysed. Results 11.7\% (15/128) and 9.4\% (12/128) of gastric cancers displayed HER2 gene amplification and protein overexpression (score 3+), respectively, with a perfect correlation between the FISH and CISH analyses. There was also a significant inverse correlation between overall survival and HER2 protein overexpression in intestinal-type gastric carcinomas (p{\textless}0.05). Conclusion Results, besides corroborating existing reports that discrepancies exist between HER2 ISH and IHC assays, also suggest the need to rigorously evaluate CISH as an independent reference standard for assessment of HER2 amplification in gastric cancers.},
	urldate = {2010-08-11},
	journal = {Journal of Clinical Pathology},
	author = {Yan, Benedict and Yau, Ee Xuan and Bte Omar, Siti Shyba and Ong, Chee Wee and Pang, Brendan and Yeoh, Khay Guan and Salto-Tellez, Manuel},
	month = aug,
	year = {2010},
	pmid = {20696687},
}

Downloads: 0